Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma
10.3760/cma.j.issn.0253-2727.2021.11.006
- VernacularTitle:新诊断原发中枢神经系统弥漫大B细胞淋巴瘤49例临床特征及预后分析
- Author:
Jia SONG
1
;
Hui LIU
;
Hongli SHEN
;
Lanzhu YUE
;
Xuejun YANG
;
Wenjing SONG
;
Cuiyun SUN
;
Shizhu YU
;
Kai DING
;
Yihao WANG
;
Lijuan LI
;
Hong YU
;
Yuanyuan SHAO
;
Chaomeng WANG
;
Shuyuan YUE
;
Rong FU
Author Information
1. 天津医科大学总医院血液内科，天津 300052
- Keywords:
Central nervous system;
Lymphoma, large B cell, diffuse;
Bruton's tyrosine kinase;
Prognosis
- From:
Chinese Journal of Hematology
2021;42(11):917-922
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The clinical characteristics of patients with primary central nervous system lymphoma-diffuse large B-cell lymphoma (PCNSL-DLBCL) and the effects of different treatment schemes on their survival and prognosis were analyzed retrospectively.Methods:A total of 49 patients with PCNSL-DLBCL who presented at the Tianjin Medical University General Hospital from July 2014 to December 2020 were included, and their clinical data were retrospectively analyzed. They were divided into four groups: the MTX group, the R-CDOP group, the BTKi-R-MTX group, and the RLZT group. The median overall survival (OS) and progression-free survival (PFS) were calculated, and the survival prognosis was compared by univariate and multivariate prognostic analysis.Results:The median OS time of the MTX group, the R-CDOP group, the BTKi-R-MTX group, and the RLZT group was 16.5 months, 4.5 months, 42 months, and not reached, respectively ( P<0.001) . The median PFS time of the MTX group, the R-CDOP group, the BTKi-R-MTX group, and the RLZT group was 7 months, 1.5 months, 20 months, and 5 months, respectively ( P=0.005) . Multivariate prognostic analysis showed that double expressor lymphoma, IESLG risk grade, and different treatment methods were the prognostic factors of PCNSL-DLBCL. Conclusion:The survival and prognosis of PCNSL-DLBCL are affected by different treatment schemes. The role of CD20 monoclonal antibody in the treatment of PCNSL-DLBCL is still controversial. The treatment scheme containing BTKi has great potential for PCNSL-DLBCL. RLZT scheme has a good prospect for elderly patients who cannot tolerate high-dose chemotherapy and radiotherapy.
